TD Cowen Maintains Buy on LENZ Therapeutics, Lowers Price Target to $45

Benzinga · 2d ago
TD Cowen analyst Stacy Ku maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $50 to $45.